NCT00883155已完成1 期
To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Sandoz
- 入组人数
- 36
- 主要终点
- Bioequivalence based on AUC and Cmax
研究概览
简要总结
To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets under Fasting Conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
排除标准
- •Positive test results for HIV or hepatitis B or C.
- •Treatment for drug or alcohol dependence.
研究组 & 干预措施
1
Experimental
Bupropion HCl 100 mg Tablets (Invamed Inc.)
干预措施: Bupropion HCl 100 mg Tablets (Invamed Inc.) (Drug)
2
Active Comparator
Wellbutrin 100 mg Tablets (Glaxo Wellcome)
干预措施: Wellbutrin 100 mg Tablets (Glaxo Wellcome) (Drug)
结局指标
主要结局
Bioequivalence based on AUC and Cmax
时间窗: 29 days
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting ConditionsDepressionNCT00864981Sandoz32
已完成
1 期
To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting ConditionsDepressionNCT00861939Sandoz28
已完成
1 期
Buspirone Hydrochloride 30mg Tablets, FastingHealthyNCT00840606Teva Pharmaceuticals USA70
已完成
1 期
Buspirone Hydrochloride 30mg Tablets, Non-FastingHealthyNCT00840398Teva Pharmaceuticals USA24
已完成
1 期
Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female SubjectsHealthyNCT02183493Boehringer Ingelheim32